Global Therapeutic Proteins and Oral Vaccines Market- Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global therapeutic proteins and oral vaccines market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The North America therapeutic proteins and oral vaccines market is expected to witness significant growth in the coming years, driven by the increasing growth strategies by market players such as signing distribution agreement in the region. For instance, in November 2021, Pfizer Inc. announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID (PF-07321332; ritonavir), subject to regulatory authorization from the U.S. Food and Drug Administration (FDA). Under the terms of the agreement, the U.S. government will acquire 10 million treatment courses to be delivered by Pfizer beginning later this year and concluding in 2022.
Therapeutic Proteins And Oral Vaccines Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients